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Abstract
Background: Epstein-Barr virus is recognized to cause lymphoproliferative disorders and is also associated with cancer.
Evidence suggests that monocytes are likely to be involved in EBV pathogenesis, especially due to a number of cellular
functions altered in EBV-infected monocytes, a process that may affect efficient host defense. Because type I interferons
(IFNs) are crucial mediators of host defense against viruses, we investigated the effect of EBV infection on the IFNa pathway
in primary human monocytes.
Methodology/Principal Findings: Infection of monocytes with EBV induced IFNa secretion but inhibited the positive
feedback loop for the amplification of IFNa. We showed that EBV infection induced the expression of suppressor of cytokine
signaling 3 (SOCS3) and, to a lesser extent, SOCS1, two proteins known to interfere with the amplification of IFNa secretion
mediated by the JAK/STAT signal transduction pathway. EBV infection correlated with a blockage in the activation of JAK/
STAT pathway members and affected the level of phosphorylated IFN regulatory factor 7 (IRF7). Depletion of SOCS3, but not
SOCS1, by small interfering RNA (siRNA) abrogated the inhibitory effect of EBV on JAK/STAT pathway activation and
significantly restored IFNa secretion. Finally, transfection of monocytes with the viral protein Zta caused the upregulation of
SOCS3, an event that could not be recapitulated with mutated Zta.
Conclusions/Significance: We propose that EBV protein Zta activates SOCS3 protein as an immune escape mechanism that
both suppresses optimal IFNa secretion by human monocytes and favors a state of type I IFN irresponsiveness in these cells.
This immunomodulatory effect is important to better understand the aspects of the immune response to EBV.
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Introduction
Epstein-Barr virus (EBV), a human gamma-herpes virus,
persists latently in over 90% of the adult population and is the
cause of infectious mononucleosis in a small proportion of carriers.
Viral reactivation is responsible for certain rare types of
lymphoproliferative disorders and cancers [1]. Although its main
target cells are B lymphocytes, EBV can spread to other cell types
[2,3]. Particularly, efficient and sustained replication of EBV
particles in primary human monocytes has been confirmed and
shown to alter a number of cellular defense mechanisms. For
example, EBV can negatively regulate monocyte secretion of
TNF-a [4] and MIP-1a [5]. In addition, EBV infection reduces
monocyte secretion of the antiviral lipid mediator prostaglandin E2
(PGE2) by targeting the enzyme cyclooxygenase-2 (COX-2)
essential for prostaglandin synthesis [6]. We also reported that
EBV infection impairs protein kinase C (PKC) function causing a
reduction in monocyte phagocytic activity [6,7]. Because mono-
cytes were shown to contribute to the spread of EBV infection [8],
these data suggest that infection of these cells may have important
implications in EBV pathogenesis.
Type I interferons (IFNs) critically contribute to host defense
against viral invaders by inducing innate responses and subsequent
adaptive immunity. Secreted IFNs function in an autocrine and
paracrine fashion to potentiate cellular antiviral mechanisms and
limit the replication and spread of the virus [9]. Upon viral sensing
by host cells, two members of the interferon regulatory factor (IRF)
family, IRF3 and IRF7, mainly activate IFN gene transcription
and initiate the first wave of IFN secretion [10]. Subsequent
binding of IFNs to their cognate receptor leads to the activation of
the JAK/STAT pathway. JAK1 and Tyk2 kinases are constitu-
tively associated with the IFN receptor subunits and upon
activation, they phosphorylate each other at critical tyrosine
residues within the intracellular domain of the receptor. STAT1
and STAT2 factors are then recruited via the phosphorylated
tyrosines, bind the activated receptor and are in turn phosphor-
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receptors through the JAK/STAT pathway creates a positive
feedback loop that prolongs activation of IFN-stimulated genes,
mediates a second wave of IFN secretion and leads to the
production of antiviral proteins such as 29-59-oligoadenylate
synthetase and dsRNA-dependent protein kinase R (PKR) [12,13].
In order to avoid excessive host tissue injury whilst protecting
effectively against infectious agents, the immune system features
regulatory mechanisms to control the production and response to
cytokines. The SOCS family of proteins comprises eight members
(SOCS1-7 and CIS) critically involved in this process [14]. SOCS1
and SOCS3 are the best-characterized family members and have
both been described to interfere with the response to IFNa
[14,15]. The kinase inhibitory region (KIR) shared by SOCS1 and
SOCS3 is sufficient to inhibit JAK tyrosine kinase activity [15]. In
addition, SOCS1 has been proposed to target itself and JAK
proteins to the microtubule organizing complex (MTOC)-
associated 20S proteasome for degradation [16]. Importantly,
recent studies have shown that several viruses such as hepatitis C
virus (HCV) [17], herpes simplex 1 virus (HSV-1) [18,19],
enterovirus [20] and respiratory syncytial virus (RSV) [21] are
capable of inducing expression of SOCS proteins and interfere
with the IFN signaling pathway.
In the present study, we hypothesized that impairment in IFNa
secretion by primary human monocytes infected with EBV
involved the activation of SOCS proteins. We tested this
hypothesis by examining SOCS1 and SOCS3 expression in
parallel with several aspects of the IFNa pathway in infected cells.
We showed that depletion of SOCS3 reduced the EBV-mediated
suppression of the IFNa pathway and that the EBV protein Zta
(also known as ZEBRA) was implicated in activating SOCS3
expression. Interference with the amplification of IFNa secretion
caused by EBV infection may constitute an essential strategy that
evolved to evade the antiviral response.
Results
EBV interferes with IFNa secretion in human monocytes
Upon recognition of pathogen-associated molecular patterns
(PAMPs), several pattern-recognition receptors (PRRs) activate the
production and secretion of type I IFN. The synthetic double-
stranded RNA analog poly(I:C) is an agonist of both TLR3 and
MDA-5 and is a known activator of type I IFN [22]. To study the
secretion of IFNa by human monocytes in the absence of potential
pathogen-derived inhibitory factor, we stimulated these cells either
once or twice with various concentrations of poly(I:C). As shown in
Figure 1A, a single stimulation with increasing concentrations of
the agonist led to the secretion of IFNa in a dose-dependent
fashion. When cells were stimulated a second time with the same
concentrations of poly(I:C), IFNa levels did not significantly differ
from what was observed after a single stimulation (Figure 1A). We
repeated the experiment using live EBV and as observed with
poly(I:C), a single monocyte treatment with increasing multiplicity
of infection (m.o.i.) also led to increased IFNa secretion (Figure 1B).
However, cells stimulated a second time with EBV secreted
significantly less cytokine at an m.o.i. of 0.1 (Figure 1B). Given that
monocytes did not become refractory to two stimulations with
high concentrations of poly(I:C), these results are consistent with
active interference on the IFNa secretion pathway caused by EBV
infection.
EBV infection induces the expression of SOCS proteins
SOCS1 and SOCS3 are known to be involved in the negative
feedback inhibition of IFNa signal transduction [14,15]. Since we
measured a decrease in IFNa secretion following a second
monocyte infection with EBV, we wanted to investigate whether
SOCS protein induction upon primary EBV infection might
contribute to this observation. Monocytes were infected with EBV
for various times and expression of SOCS1 and SOCS3 was
evaluated at both the mRNA and protein levels. Transcription of
both SOCS1 and SOCS3 was increased following EBV infection,
reaching maximum levels after 30 minutes (Figure 2A). Increased
SOCS expression was also confirmed at the protein level since
SOCS1 expression was increased at 60 minutes post-infection
whilst SOCS3 expression progressively increased from 20 to 60
minutes post-infection (Figure 2B). Thus, EBV infection causes the
upregulation of two SOCS proteins involved in the modulation of
the IFN pathway.
EBV-mediated SOCS3 activation causes the inhibition of
the JAK/STAT pathway
The cellular response to IFNa occurs via the JAK/STAT
pathway downstream of the IFNa receptor [11]. To further dissect
the response of monocytes to IFNa, we first monitored the
phosphorylation of STAT1 and STAT2 in response to single or
dual IFNa stimulation in the absence of viral infection. As shown
in Figure 3A, a 15-minute stimulation with IFNa caused an
increase in phospho-STAT1 and phospho-STAT2 levels. The
amounts of phospho-STAT1 and phospho-STAT2 were both
reduced following a prolonged 20-hour exposure to IFNa,a s
Figure 1. Effect of EBV infection on IFNa secretion by human
monocytes. Monocytes (2610
6 cells) were stimulated with (A)
poly(I:C) or (B) EBV for 20 hours. Following stimulation, cell-free
supernatants were harvested (1
st stimulation). Cells were restimulated
a second time with poly(I:C) or EBV for another 20 hours (2
nd
stimulation) and cell-free supernatants were harvested for IFNa
determination by ELISA. Data are representative of three independent
experiments. *p#0.05 when compared to EBV 1
st stimulation.
doi:10.1371/journal.pone.0011908.g001
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PLoS ONE | www.plosone.org 2 July 2010 | Volume 5 | Issue 7 | e11908compared to a 15-minute stimulation only. Importantly, a 15-
minute treatment with IFNa following a 20-hour exposure to
IFNa caused an increase in both phospho-STAT1 and phospho-
STAT2 compared to a 20-hour exposure only (Figure 3A). These
results demonstrate that uninfected monocytes are still responsive
to IFNa stimulation following prolonged exposure to this cytokine
and establish a model system that can then be used to study the
effect of EBV infection on the IFNa pathway.
SOCS1 and SOCS3 suppress IFNa signaling downstream of
the IFNa receptor by blocking signal transduction through the
JAK/STAT pathway [14]. To investigate whether EBV infection
correlates with an impairment in JAK/STAT signaling down-
stream of the IFNa receptor, we first monitored the phosphory-
lation of Tyk2, Jak1, STAT1 and STAT2 in monocytes infected
with EBV alone or infected and restimulated with IFNa.
Triggering of the IFNa receptor through a short stimualtion with
IFNa induced a strong activation of all members of the pathway
(Figure 3B). Whilst infection of monocytes with EBV for 20 hours
led to the phosphorylation of Jak1, STAT1 but not Tyk2 nor
STAT2, increased phosphorylation of these proteins could not be
observed upon restimulation of infected cells with IFNa
(Figure 3B). Thus, EBV infection causes a blockage in the
activation of the JAK/STAT pathway, a mechanism consistent
with the action of SOCS1 and SOCS3.
To directly address the role of SOCS1 and SOCS3 in
interfering with JAK/STAT signaling upon EBV infection, we
used siRNA to silence the expression of these proteins. As shown in
Figure 3C, both SOCS1- and SOCS3-targetting siRNA reduced
expression levels of SOCS1 and SOCS3 respectively. Using both
untransfected and transfected cells, we monitored phosphorylation
of STAT1 and STAT2 under the same experimental conditions as
in Figure 3B. In untransfected cells, akin to what was previously
observed, a 15-minute IFNa stimulation of monocytes already
infected with EBV for 20 hours did not increase levels of phospho-
STAT1 and phospho-STAT2 as compared to EBV infected cells
only (Figure 3D). Transfection of cells with siRNA against SOCS1
had no major effect on the phosphorylation of both proteins,
however, inhibition of SOCS3 caused a marked increase in
phospho-STAT1 and phospho-STAT2 in dually stimulated cells.
Overall, these results indicate that EBV infection of monocytes
causes the inhibition of the JAK/STAT pathway via SOCS3.
Activation of IRF3 and IRF7 during EBV infection
Although SOCS1 and SOCS3 are known to inhibit the JAK/
STAT-mediated second wave of IFNa production, we were
interested in whether IRF3 and IRF7, implicated in the first wave
of type I IFN production, might also be affected by EBV infection.
Indeed, it has been described that the JAK/STAT pathway
modulates IRF7 expression via the formation of the interferon-
stimulated gene factor 3 (ISGF3) complex [23,24]. To verify the
activation of both IRFs during primary EBV infection and upon
restimulation, monocytes were stimulated once or twice with EBV
and the presence of phosphorylated forms of IRF3 and IRF7 was
evaluated by immunoblotting. Following a single stimulation with
EBV, phospho-IRF3 and phospho-IRF7 were detected as early as
6 hours (Figure 4). Whilst levels of phospho-IRF3 decreased
thereafter, phospho-IRF7 levels progressively increase from 6 to
24 hours. Upon a second stimulation with EBV, phospho-IRF3
was further induced after 6 hours and then progressively
decreased to a much greater extent to what was observed during
the first stimulation. However, in the case of phospho-IRF7, whilst
levels of phosphorylation were detected after a second EBV
stimulation, no further increase of phosphorylation levels was
observed. These results suggest that IRF3 and IRF7 can be
activated by EBV but that IRF7 activity can be progressively
affected after a prolonged stimulation with EBV.
SOCS3 plays a determinant role in the suppressive effect
of EBV on IFNa secretion
Our results highlighted a putative role for SOCS3 in the EBV-
mediated suppression of IFNa secretion. To confirm its suppres-
sive role, monocytes were transfected with siRNA directed against
SOCS1 or SOCS3 and were infected once or twice with EBV. A
first stimulation with EBV induced high levels of IFNa secretion,
regardless of the siRNA transfected, as compared to poly(I:C)
stimulation (Figure 5). When cells were stimulated a second time
with EBV, the suppressive effect of the virus was detectable in
control siRNA-transfected monocytes. Although SOCS1-target-
ting siRNA did not impact IFNa secretion after the second
Figure 2. Expression of SOCS proteins following EBV infection
of human monocytes. Monocytes (5610
6) were stimulated or not
with EBV for the indicated time. (A) The expression of SOCS1 and SOCS3
proteins was evaluated by RT-PCR using described primers (Table 1) or
(B) by Western blot analysis using specific anti-SOCS1 antibodies, anti-
SOCS3 antibodies and anti-Actin as loading control. Densitometry was
performed and represents fold protein induction (relative to 0 min.) 6
std. dev. of experiments performed in duplicate. Data are representative
of three independent experiments.
doi:10.1371/journal.pone.0011908.g002
EBV Activates SOCS3
PLoS ONE | www.plosone.org 3 July 2010 | Volume 5 | Issue 7 | e11908Figure 3. Effect of EBV infection on the activation of the JAK/STAT pathway. (A) Monocytes were incubated in the presence of IFNa
(1000 U/ml) for 15 minutes and 20 hours. Following incubation (20 hours), cells were restimulated or not with IFNa for 15 minutes. The expression of
phospho(p)STAT1, and phospho(p)STAT2 proteins was evaluated by Western blot analysis. Membranes were also probed with anti-Actin as a loading
control. Densitometry was performed and represents fold protein induction (relative to non stimulated cells) 6 std. dev. of experiments performed in
duplicate. (B) Monocytes (5610
6) were treated with IFNa (1000 U/ml) for 15 minutes, with EBV for 20 hours or were pre-incubated for 20 hours in the
presence of EBV followed by a stimulation with IFNa for 15 minutes. The expression of phospho(p)Tyk2, phospho(p)JAK1, phospho(p)STAT1, and
phospho(p)STAT2 proteins was evaluated by Western blot analysis. Membranes were also probed with anti-Tyk2, JAK1, STAT1 and STAT2 as a loading
EBV Activates SOCS3
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cytokine secretion. These results confirm the direct involvement of
SOCS3 in the suppressive effect of EBV on IFNa secretion in
human monocytes.
The viral protein Zta causes the transactivation of SOCS3
The EBV protein Zta is a basic leucine zipper (bZIP)
transcription factor with many described functions including the
interaction with host proteins and the modulation of cellular gene
expression [25]. As shown in Figure 6A, Zta is strongly expressed
in EBV-infected monocytes, further supporting the observation
that EBV can efficiently infect this cell type [26]. In light of the
many reports describing the modulation of immune-related host
genes by Zta [25,27], we wanted to investigate whether this viral
transactivator could induce the expression of SOCS3. To do so,
HEK293 cells were co-transfected with a reporter vector driven by
the SOCS3 promoter along with either a vector encoding wild-
type Zta (Zta) or a vector encoding a mutated form of Zta (DZta)
that has lost its normal transactivation activity [28]. In this system,
SOCS3 promoter activity was enhanced proportionally to the
amount of transfected Zta vector, however, such activation was
not observed using the DZta vector (Figure 6B). To confirm the
ability of Zta to induce SOCS3 expression and modulate the JAK/
STAT pathway, we transfected human monocytes with the Zta or
the DZta vector or with a mock control prior to stimulation with
IFNa and monitored levels of SOCS3 and phospho-STAT2 by
immunoblot. The amount of SOCS3 protein was enhanced in
cells transfected with the Zta vector as compared to the cells
transfected with the DZta vector or the mock control (Figure 6C).
In addition, increased SOCS3 expression in cells transfected with
the Zta vector was accompanied by a marked decrease in
phospho-STAT2 levels as compared to the cells transfected with
the control vector (Figure 6C). Finally, we observed a partial
restoration of phospho-STAT2 levels in cells transfected with the
DZta vector. Thus, EBV protein Zta can transactivate SOCS3
expression in order to interfere with the IFNa response pathway in
human monocytes.
Discussion
In the present study, we demonstrated that infection of primary
human monocytes with EBV leads to the inhibition of the IFNa
signal transduction pathway and hence, to an impairment in the
Figure 4. Effect of EBV infection on IRF3 and IRF7 activation. 1
st
EBV stimulation: Monocytes (5610
6 cells) were stimulated or not with
EBV for the indicated times and expression of phosphorylated forms of
IRF3 and IRF7 proteins was evaluated by Western blot analysis. 2
nd EBV
stimulation: Monocytes were first stimulated with EBV for 20 hours,
washed and then restimulated a second time with EBV for the indicated
times. Expression of phosphorylated forms of IRF3 and IRF7 proteins
was evaluated by Western blot analysis. Membranes were also probed
with anti-Actin as a loading control. Densitometry was performed and
represents fold protein induction (relative to 0 h) 6 std. dev. of
experiments performed in duplicate. Data are representative of three
independent experiments.
doi:10.1371/journal.pone.0011908.g004
Figure 5. siRNA against SOCS3 restores IFNa secretion
following EBV infection. Monocytes (2610
6 cells) were transfected
with 165 nM siRNA targeting SOCS1 or SOCS3. Scramble siRNA was
used as control. Twenty-four hours after transfection, cells were
stimulated with EBV for 20 hours (1
st EBV stimulation). Following this
first EBV stimulation, medium was replaced and cells were stimulated a
second time with EBV (2
nd EBV stimulation) for an additional 20 hours.
Cell-free supernatants were then harvested for IFNa determination.
Data are representative of three independent experiments. Values in
percentage represent the inhibition in IFNa secretion relative to the first
respective EBV stimulation. *p#0.05 compared to cells transfected with
scramble siRNA and stimulated a second time with EBV. SCR: scrambled
siRNA.
doi:10.1371/journal.pone.0011908.g005
control. (C) Monocytes (2610
6 cells) were transfected with 165 nM siRNA targeting SOCS1 or SOCS3 prior to EBV stimulation for 1 hour. Scramble
siRNA was used as control. The expression of SOCS1 and SOCS3 was evaluated by Western blot analysis. Densitometry was performed and represents
fold protein induction (relative to non-transfected cells) 6 std. dev. of experiments performed in duplicate. (D) Monocytes (2610
6 cells) were either
left untransfected or were transfected with siRNA targeting SOCS1 or SOCS3 and stimulated as in (B). The expression of phospho(p)STAT1 and
phospho(p)STAT2 proteins was evaluated by Western blot analysis. Membranes were also probed with anti-STAT1 and STAT2 as a loading control.
Data are representative of three independent experiments. NS: non-stimulated; NT: non-transfected; SCR: scrambled siRNA.
doi:10.1371/journal.pone.0011908.g003
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a hypothetical model of EBV-mediated negative regulation of IFN
response and secretion in monocytes (Figure 7). According to this
model, virion entry into the cell activates IRF3 and IRF7 leading
to a first wave of type I IFN production. At the same time, EBV
modulates SOCS3 expression in order to inhibit IFN receptor-
mediated intracellular signaling through the JAK/STAT pathway.
The latter results in a marked attenuation of the amplification loop
initiated by the binding of type I IFNs to their cognate receptor. As
a consequence, interferon-stimulated genes (ISGs) and IRF7 are
negatively regulated and the second wave of IFNa secretion is
impaired.
The importance of IFNs, originally discovered because of their
ability to protect cells from viral infections, is highlighted by the
observation that most viruses have evolved anti-IFN strategies
[29]. Several studies have investigated mechanisms used by EBV
to regulate the expression of IFNa and IFN-inducible genes. On
one side, the early lytic EBV nuclear protein SM and the latent
membrane protein 1 (LMP1) were reported to induce phosphor-
ylation of STAT1 and the expression of ISGs [30,31]. To
counteract this cellular recognition event, EBV was shown to
downregulate IFN-induced transcription via the viral protein
EBNA-2 [32,33] and to increase IFN receptor degradation via
LMP2A and LMP2B [34] whilst EBV encoded EBER RNAs were
found to be involved in IFN resistance by binding to PKR but
failing to activate it [35,36]. Another interesting mechanism of
interference with IFN secretion was demonstrated by Cohen and
Lekstrom who showed that EBV BARF1 gene (known to encode a
soluble colony-stimulating factor receptor) inhibits IFNa secretion
by mononuclear cells [37]. To our knowledge, we are the first to
report SOCS protein activation during EBV infection of
monocytes.
Viral-mediated induction of SOCS proteins is currently
emerging as a key mechanism of immune evasion. Indeed,
Figure 6. Activation of SOCS3 by the viral protein Zta. (A) Monocytes (5610
6) were mock- or EBV-stimulated for 20 hours and expression of
the EBV protein Zta was evaluated by Western blot analysis. (B) HEK293 cells were transiently co-transfected with a vector encoding WT Zta or
mutated Zta (DZta) at indicated concentrations along with a SOCS3 promoter-driven luciferase reporter vector. Luciferase assay was performed
48 hours post-transfection. (C) Monocytes (5610
6) were transfected with 300 ng of either Zta vector or DZta vector or mock vector control (CTRL).
Forty-eight hours following transfection, monocytes were stimulated with IFNa (1000 U/ml) for 15 minutes. The expression of SOCS3 and
phospho(p)STAT2 proteins was evaluated by Western blot analysis. Membranes were also probed with anti-Actin as a loading control. Densitometry
was performed and represents fold protein induction (relative to mock-transfected cells) 6 std. dev. of experiments performed in duplicate. Data are
representative of two independent experiments. *p#0.05 compared to non-transfected control cells. NS: non-stimulated; NT: non-transfected.
doi:10.1371/journal.pone.0011908.g006
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shown to activate SOCS3 in infected epithelial cells leading to the
downregulation of the JAK/STAT cascade [19]. The authors of
the study concluded that HSV-1-induced SOCS3 was mainly
responsible for the suppression of IFN signaling. In the case of
EBV, we also observed that SOCS1 was induced in infected
monocytes. Whilst the use of siRNAs directed against SOCS3
confirmed its role in EBV-mediated suppression of the JAK/
STAT pathway and IFNa secretion, SOCS1 siRNA had no
significant effect. The incomplete restoration of IFNa secretion
with the use of SOCS3 siRNA shown in Figure 5 could either be
explained by the difficulty to achieve high transfection efficiency in
human monocytes coupled with the incomplete abolishment of
SOCS expression by siRNA or by other viral-induced mechanisms
targeting IFN signaling. Phosphatases such as protein tyrosine
phosphatase 1B (PTP1B) [38] and SHP-2 [39] can interfere with
the JAK/STAT pathway and represent candidate proteins
potentially modulated by EBV. Other SOCS proteins such as
CIS may also play a role. A recent study by Hashimoto et al.,
investigated the induction of all eight SOCS proteins during RSV
infection and found that SOCS1, SOCS3 and CIS were activated
[21]. Suppression of the three proteins by siRNA inhibited viral
replication and activated type I IFN signaling. Although we do not
conclude that SOCS3 activation is sufficient for EBV-mediated
interference with IFNa secretion, it does represent an important
mechanism as demonstrated for HCV, HSV-1, enterovirus and
RSV [17,18,19,20,21].
The transactivation of SOCS3 by Zta puts forward a new role
for this viral effector protein. Zta is composed of a C-terminal
transactivation domain, a central basic region that mediates DNA
contact and a characteristic bZIP domain extending towards the
N-terminus. Expression of Zta on its own is sufficient to disrupt
EBV latency and this protein has a major role in EBV-associated
cell transformation by modulating cellular gene expression and
interacting with host cell-cycle proteins [25]. In our study, Zta was
sufficient to induce SOCS3 expression and inhibit STAT2
phosphorylation upon IFNa stimulation of monocytes. Whilst
SOCS3 expression could not be recapitulated with mutated Zta,
STAT2 phosphorylation was only partly restored following IFNa
treatment in this context. The DZta vector encodes the full-lenght
Zta protein with two amino acid substitutions in the transactiva-
tion domain, only affecting part of its transcriptional activity [28].
Thus, DZta-mediated activation of other IFN signaling modula-
tory factors may account for the incomplete restoration of STAT2
phosphorylation. A possible factor is IL-10, which is known to be
activated by Zta [40] and to inhibit IFNa-induced phosphoryla-
tion of STAT proteins [41]. Certainly, the pleiotropic action of Zta
during EBV infection is only beginning to be fully revealed and its
Figure 7. Proposed mechanism for EBV-mediated interference with type I IFN secretion by human monocytes. Following entry into the
cell, EBV induces IRF3/7 activation leading to the initial production of IFNa/b. EBV infection also induces the synthesis of SOCS3 protein which results
in inhibition of IFN receptor (IFNR) signaling and also in inhibition of the amplification of IFNa/b production. ISGs: interferon-stimulated genes. Black
lines indicate ‘‘activation’’ and red lines indicate ‘‘suppression’’. Red dotted lines represent suppressive effects of SOCS protein activation on JAK/STAT
signaling events.
doi:10.1371/journal.pone.0011908.g007
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future investigations.
One example of such suppressive effect is the modulation of
IRF7 by Zta. In a study by Hahn and colleagues, IRF7 activation
was negatively regulated by Zta [42]. Zta did not affect IRF7 levels
but expression of both IRF7 and Zta were found to be directly
associated. Since Zta is a nuclear protein and that phosphorylated
IRF7 translocates to the nucleus, the authors postulated that
interaction between Zta and activated IRF7 might be responsible
for downmodulating the transcription of IRF7 target genes. In our
study, we monitored the phosphorylation status of endogeneous
IRF3 and IRF7 in human monocytes. As opposed to phospho-
IRF3, which could still be induced upon secondary stimulation
with EBV, phospho-IRF7 progressively decreased under this
condition. Based on our results, we suggest that the effect of Zta on
IRF7 is indirect and implicates the inhibition of the JAK/STAT
pathway by SOCS, thereby causing a decrease in ISGF3-driven
IRF7 expression. It is interesting to note that whilst our proposed
mechanism differs from that stated by Hahn et al., both
mechanisms are not mutually exclusive. As pointed out by the
authors, IRF7, which was first cloned as a transcriptional regulator
of the central EBV latency gene EBNA-1, is intricately associated
with EBV infection [42]. Indeed, accumulating evidence highlights
the use of different and/or redundant strategies by EBV to
modulate IRFs expression and activity and interfere with the
antiviral activity of type I IFNs [43,44,45]. Further research is
needed to ask whether those strategies differ between cell types or
upon primary EBV infection in comparison with reactivation from
a latent infection.
Our study was performed using primary human monocytes in
which productive EBV infection and viral-mediated alteration of
several cellular functions have been demonstrated [3]. Here, we
have shown that EBV infection induces SOCS3 activation via Zta
and alters the IFNa signaling pathway. Using such a strategy, EBV
might be able to survive longer within monocytes and optimize its
dissemination. Furthermore, because monocytes are recognized as
important antigen presenting cells linking the innate and adaptive
immunity, suppression of their biological functions by EBV may
thus affect the host immune response. Emerging therapeutic
approaches aimed at downregulating SOCS gene expression [46]
could possibly be beneficial against EBV infection by enhancing
the innate antiviral activity of monocytes.
Materials and Methods
Ethics statement
Heparinized blood was obtained from healthy donors after
written informed consent from all individuals in accordance with
an Internal Review Board-approved protocol at CHUQ Research
Center (Centre Hospitalier Universite ´ Laval).
Isolation, purification and culture of human monocytes
Peripheral blood mononuclear cells (PBMCs) were isolated by
centrifugation of heparinized blood obtained from healthy donors
over Lymphocyte Separation Medium (Wisent Inc., St-Bruno, QC,
Canada). PBMCs were next allowed to adhere onto autologous
serum-treated petri dishes in order to separate monocytes from the
lymphocyte population. Monocytes were further enriched by cell
sorting (FACSAria, BD Biosciences, MD, USA) which resulted in at
least 99% pure monocyte suspension as determined by flow
cytometry analysis using anti-CD14 monoclonal antibodies. Cell
viability was more than 99% as tested by trypan blue dye exclusion
procedure. Isolated monocytes were resuspended in RPMI-1640
supplemented with 10% fetal bovine serum (FBS).
Viral preparations
EBV strain B95-8 was produced as described previously [26].
Briefly, B95-8 cells were cultured in RPMI 1640 medium
supplemented with 10% FBS in the presence of 20 ng/ml phorbol
myristate acetate (PMA), a known inducer of viral reactivation.
Cell-free supernatants were filtered through a 0.45 mm pore size
filter and viral particles were concentrated by ultracentrifugation.
Viral particles were resuspended in RPMI 1640 medium, titrated
as described [47] and stored at 2150uC until use. Cell-free
supernatants collected from B95-8-infected cells not exposed to
PMA were processed as described above and used as mock
controls.
Monocyte stimulation
Enriched monocytes were incubated with infectious EBV
particles at the indicated multiplicity of infection (m.o.i.) or were
transfected with poly(I:C) (Sigma-Aldrich, Oakville, ON, Canada)
at indicated concentrations using lipofectamine reagent (Invitro-
gen, Burlington, ON, Canada) and cultured for 20 hours (first
stimulation). Infected cells were then washed once in HBSS buffer
and resuspended in fresh culture medium. Cells were then
restimulated a second time with EBV, poly(I:C), or human IFNa
(PBL Biomedical Laboratories, Piscataway, NJ) for indicated times
(second stimulation). Following first and second stimulations, cell-
free supernatants were harvested for IFNa quantitation by ELISA
assay (PBL Biomedical Laboratories, Piscataway, NJ) or cells were
lysed for Western blot or RT-PCR analyses as described below.
RNA isolation and RT-PCR amplification
Untreated and EBV-treated monocytes were cultured for
various periods of time before RNA extraction. Total RNA from
monocytes was isolated using Trizol reagent (Invitrogen, Burling-
ton, ON, Canada) according to the manufacturer’s instructions.
One microgram of DNase-treated RNA was reverse transcribed to
cDNA with oligo (pdT) primers in a 20 ml reaction containing 20
U of SuperScript II RNase H Reverse Transcriptase and 1 U of
RNase inhibitor (Invitrogen, Burlington, ON, Canada). A volume
of 5 ml cDNA samples was subjected to 35 cycles of PCR
amplification in 50 ml of PCR mixture containing 0.5 U of Taq
DNA Polymerase and 1.5 mg of the appropriate primers. Primers
used in this study are depicted in Table 1. GAPDH was used as
internal control.
Western blot analysis
Monocytes were incubated with appropriate agonists for
indicated times, lysed (TAE buffer 16, 1 mM EDTA, 27 mM
sucrose, 1% Triton X-100) and boiled for 5 minutes after addition
of sample buffer (150 mM Tris pH 6.8, 1.2% SDS, 0.33%
Table 1. RT-PCR primers used in this study.
Primer names Sequences
Amplicon
sizes
SOCS-1 sense 59CACGCACTTCCGCACATTCC39 300 bp
SOCS-1 antisense 59TCCAGCAGCTCGAAGAGGCA39
SOCS-3 sense 59TCACCCACAGCAAGTTTCCCGC39 589 bp
SOCS-3 antisense 59GTTGACGGTCTTCCGACAGAGATGC39
GAPDH sense 59CCACCCATGGCAAATTCCATGGCA39 598 bp
GAPDH antisense 59TCTAGACG GCAGGTCAGGTCCACC39
doi:10.1371/journal.pone.0011908.t001
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Proteins were separated by SDS-polyacrylamide gel electrophore-
sis (SDS-PAGE), under reducing conditions followed by transfer
onto a nitrocellulose membrane. Membranes were pretreated in
blocking solution containing 5% (w/v) dry milk in Tris-buffered
saline-Tween 20 for 1 hour at room temperature and then
incubated overnight at 4uC with anti-pIRF3, anti-phospho or total
JAK1, anti-phospho or total Tyk2, anti-phospho or total STAT1,
anti-phospho or total STAT2, (Cell Signaling, Danvers, MA), anti-
IRF3, anti-IRF7, anti-SOCS-1, anti-SOCS-3, or anti-b-actin
(Santa Cruz Biotechnology, Santa Cruz, CA). Membranes were
washed four times with Tris-buffered saline-Tween 20 and
incubated either with HRP-conjugated sheep anti-mouse Ig or
donkey anti-rabbit IgG antibodies (Jackson ImmunoResearch
Laboratories Inc., West Grove, PA) for 1 hour. Immunoreactive
proteins were revealed by enhanced chemiluminescence (Perkin
Elmer, Woodbridge, ON, Canada). Densitometry analysis was
performed using the Image J software and relative protein levels
were normalized to relative b-actin levels.
Small interfering RNA assay
Purified primary monocytes (2610
6 cells) were transfected with
165 nM of small interfering RNA against SOCS-1 (Sense: 59-
GCAUUAACUGGGAUGCCGUtt-39 Antisense: 59-ACGGCA-
UCCCAGUUAAU GCtg-39) or SOCS-3 (Sense: 59-GAAC-
CUGCG CAUCCAGUGUtt-39 Antisense: 59-ACACUGGAU-
GCGCAGGUUCtt-39) (Applied Biosystems/Ambion, Austin,
TX) using lipofectamine according to the manufacturer’s instruc-
tion. Scramble siRNA was used as control. Four hours post-
transfection, cells were washed once in HBSS buffer and
resuspended in culture medium in order to avoid cellular toxicity
due to siRNA transfection. Twenty-four hours post-transfection,
cells were stimulated as described and cell-free supernatants were
harvested and tested for the presence of IFNa by ELISA or cells
were lysed for Western blot analysis.
Luciferase Assay and Plasmid Transfection
Human embryonic kidney (HEK293) cell line (ATCC,
Manassas, VA) was cultured in Dulbecco modified Eagle medium
(DMEM) supplemented with 10% heat-inactivated FBS. HEK293
cells (5610
4 cells/ml) were transiently co-transfected with 100, 200
or 300 ng of either pcDLSRa-Zta wt or pcDLSRa-Zta mutated
(DZta) (Q34A and D35A) [28] plasmids kindly provided by Dr.
Paul M. Lieberman using Escort transfection reagent (Sigma-
Aldrich, Oakville, ON, Canada) along with 100 ng pGL3-
pSOCS3 luciferase reporter plasmid. Forty-eight hours following
transfection, cells were lysed in luciferase buffer (1% Triton, 10%
glycerol, 20 mM Tris phosphate, pH 7.8) and luciferase activity
was measured by luminometry. Relative light units (RLU) were
normalized by protein dosage using BCA protein assay kit (Pierce
Biotechnology, Rockford, IL). When indicated, monocytes (6610
6
cells/ml) were transfected with 300 ng of either pcDLSRa-Zta wt,
pcDLSRa-Zta (DZta) or mock control (pcDL-SRa296) plasmids
using Lipofectamine 2000 (Invitrogen, Burlington, ON, Canada).
Four hours following transfection, monocytes were supplemented
with 10% FBS. Forty-eight hours later, monocytes were stimulated
with IFNa (1000 U/ml) for 15 minutes and expression of SOCS3
and phospho(p)STAT2 proteins was evaluated by Western blot
analysis. Membranes were also probed with anti-Actin as loading
control.
Statistical analysis
Data were analyzed by one-tailed analysis of variance
(ANOVA) followed by Newman-Kheuls post-hoc test using
PRISM3 software. Differences were considered significant at
p#0.05.
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